Project Name: Optimising the Delivery of Oral eBC SACT for Patients with Breast Cancer

Project Summary: 

This collaborative working project aims to develop and test a digital remote pathway for patients with early breast cancer (eBC) to enable the remote monitoring and delivery of medications directly to patients without them needing to attend the hospital sites through supporting the roles of a band 8d Programme Director, plus a Band 7 (0.5 FTE) Connect Analyst role for 18 months. 

The Programme Director will lead the project and will be embedded in the Royal Marsden transformation structure. The Connect Analyst time will be used to make necessary associated changes to the Epic system.

The tasks undertaken by the new workforce will be as follows:

  • Full implementation of a digitally supported eBC SACT pathway
  • Creation and testing of the e-PROMs tools to support remote patient assessment.
  • Assessment of the workforce required to deliver the agreed working model
  • Creation and delivery of the workforce model to ensure sustainability
  • Creation of sustainable model for the delivery of medication to this patient group
  • Creation of a sustainable model for the undertaking of remote blood tests for these patients.
  • Creation of patient education materials regarding their current and future management
  • Sustainable business plan to deliver this ongoing model of care 

Expected Benefits: 

ANTICIPATED BENEFITS FOR PATIENTS:

  • Care closer to home
  • Improved patient experience
  • Improved access to health information
  • Patient information video

 ANTICIPATED BENEFITS FOR THE ORGANISATION:

  • Progress towards strategic priorities
  • Reduction in face to face outpatient activity
  • Increase in number of new patients that can be seen
  • Sustainable model of care
  • Increasing outpatient capacity

ANTICIPATED BENEFITS FOR NOVARTIS 

  • Transferrable learnings around sustainable capacity building in outpatients
  • Optimal use of medicines in line with local/national guidance (including Novartis medicines) in appropriate patients.
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation
  • Intent to publish for dissemination to the wider healthcare community via the Novartis website, the Executive Summary and Outcomes summary as a minimum, but not limited to the Executive Summary and Outcomes summary

Start Date & Duration: April 2026 for 28 months.

FA-11634125 | March 2026